Maryland is currently home to 2668 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Baltimore, Bethesda, Rockville and Annapolis. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
SELUTION 4 De Novo Small Vessel IDE Trial
NCT05946629
Recruiting
Prospective, randomized controlled, single-blind, multicenter, clinical trial to demonstrate the safety and efficacy of the SELUTION SLR 014 PTCA DEB for treatment of de novo lesions in small coronary vessels, defined as reference vessel diameter (RVD) of 2.00 mm to 2.75 mm, in support of a pre-market approval (PMA) application to the United States (US) FDA. The Study will enroll up to 910 randomized subjects, up to 30 subjects in a parallel angiographic substudy, and up to 20 subjects in a par... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/03/2025
Locations: Johns Hopkins, Baltimore, Maryland
Conditions: Coronary Artery Disease
Register for Updates
Phase 1/2 Study of Avutometinib (VS-6766) + Sotorasib With or Without Defactinib in KRAS G12C NSCLC Patients
NCT05074810
Recruiting
This study will assess the safety and efficacy of avutometinib (VS-6766) in combination with sotorasib with or without defactinib in patients with KRAS G12C Non-Small Cell Lung Cancer (NSCLC) in patients who have been exposed to prior G12C inhibitor and those who have not been exposed to prior G12C inhibitor.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/03/2025
Locations: Maryland Oncology & Hematology, P.A., Rockville, Maryland
Conditions: Non Small Cell Lung Cancer, KRAS Activating Mutation
Register for Updates
Study of Selinexor in Combination with Ruxolitinib in Myelofibrosis
NCT04562389
Recruiting
This is a global, multicenter, 2-part study to evaluate the efficacy and safety of selinexor plus ruxolitinib in JAK inhibitor (JAKi) treatment-naïve myelofibrosis (MF) participants. The study will be conducted in two phases: Phase 1 (open-label) and Phase 3 (double-blind). Phase 1 (enrollment completed) was an open-label evaluation of the safety and recommended Phase 2 dose (RP2D) of selinexor in combination with ruxolitinib and included a dose escalation using a standard 3+3 design (Phase 1a)... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/03/2025
Locations: Maryland Oncology Hematology-Satellite, Annapolis, Maryland
Conditions: Myelofibrosis
Register for Updates
Study Assessing CLENPIQ As Bowel Preparation for Pediatric Colonoscopy
NCT04113382
Recruiting
Bowel preparation for pediatric colonoscopy.
Gender:
ALL
Ages:
Between 2 years and 8 years
Trial Updated:
02/03/2025
Locations: Ferring Investigational Site, Baltimore, Maryland
Conditions: Bowel Preparation
Register for Updates
AMI Construction in Lower Extremity Residual Limbs
NCT04063592
Recruiting
This study will involve the development of a novel approach to lower extremity residual limb surgical revision that offers the promise of augmenting volitional motor control, restore proprioception and reverse atrophy
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
02/03/2025
Locations: Walter Reed National Military Medical Center, Bethesda, Maryland
Conditions: Amputation
Register for Updates
A Novel Approach to Upper Extremity Amputation to Augment Volitional Control and Restore Proprioception
NCT03882073
Recruiting
The hypothesis of this research protocol is that the investigators will be able to redesign the manner in which upper limb amputations are performed so as to enable volitional control of next generation prosthetic devices and restore sensation and proprioception to the amputated limb. The investigators will test this hypothesis by performing modified above elbow or below elbow amputations in ten intervention patients, and compare their outcomes to ten control patients who have undergone traditio... Read More
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
02/03/2025
Locations: Walter Reed National Military Medical Center, Bethesda, Maryland
Conditions: Amputation
Register for Updates
Social Experiences and Demographic Factors in the Regulation of Immune Cells
NCT06519487
Recruiting
Immune-mediated inflammatory diseases are a health burden for approximately seven percent of the population of Western nations. Preliminary data suggest variations in ethnic identity and/or geography influence discrimination experiences and inflammatory response trends. This study investigates how geography, ethnicity, and laboratory manipulation of discrimination experiences affect immune cell function and genomic regulation. Flow cytometry and immune cell stimulation will test monocytes collec... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/31/2025
Locations: Morgan State University, Baltimore, Maryland
Conditions: Perceived Discrimination, RNA, Inflammatory Response
Register for Updates
Dose Escalation Trial of Safety, Pharmacokinetic/Pharmacodynamic and Preliminary Clinical Activity of Briquilimab in Adult Patients with Chronic Spontaneous Urticaria (CSU)
NCT06162728
Recruiting
This trial will be performed as a three-part dose escalating clinical trial where Parts 1 is open label and Parts 2 and 3 are randomized, double-blinded, and placebo-controlled. The trial is intended to determine the safety and tolerability and assess the preliminary efficacy of briquilimab in adult participants with chronic spontaneous urticaria (CSU), who remain symptomatic despite treatment with H1 antihistamines and omalizumab. Additionally, pharmacokinetic (PK) properties of briquilimab, a... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/31/2025
Locations: Site 101, Baltimore, Maryland
Conditions: Chronic Spontaneous Urticaria
Register for Updates
Individual Variations of Taste and Smell Perception in Alcohol Use Disorder (AUD)
NCT05677321
Recruiting
Background: Alcohol use disorder (AUD) is the most common substance use disorder in the world. Long-term AUD can affect a person s sense of taste and smell. This natural history study will compare alcohol drinking behaviors and measures of taste and smell in people with and without AUD. Objective: To understand how alcohol use changes the senses of taste and smell. Eligibility: People aged 18 to 65 years with or without AUD. Design: Participants will be screened. They will have several te... Read More
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
01/31/2025
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Alcohol Use Disorder
Register for Updates
Surgery With or Without Neoadjuvant Chemotherapy in High Risk RetroPeritoneal Sarcoma
NCT04031677
Recruiting
This is a multicenter, randomized, open label phase lll trial to assess whether preoperative chemotherapy, as an adjunct to curative-intent surgery, improves the prognosis of high risk DDLPS (dedifferentiated Liposarcoma) and LMS (Leiomyosarcoma) patients as measured by disease free survival. After confirmation of eligibility criteria, patients will be randomized to either the standard arm or experimental arm.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/30/2025
Locations: Johns Hopkins Univ/Sidney Kimmel Cancer Center, Baltimore, Maryland
Conditions: Retroperitoneal Sarcoma, Liposarcoma, Leiomyosarcoma
Register for Updates
Tailored Axillary Surgery With or Without Axillary Lymph Node Dissection Followed by Radiotherapy in Patients With Clinically Node-positive Breast Cancer (TAXIS)
NCT03513614
Recruiting
RATIONALE: The use of tailored axillary dissection as a tailored procedure will avoid surgical overtreatment by selectively removing the lymph nodes that are affected by the cancer, thereby sparing many women the unnecessary complications of a radical surgery, providing a better quality of life while keeping the same efficacy. PURPOSE: The phase III trial is evaluating the optimal treatment for breast cancer patients in terms of surgery and radiotherapy.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/30/2025
Locations: Walter Reed National Military Medical Center, Bethesda, Maryland
Conditions: Node-positive Breast Cancer
Register for Updates
Pregabalin Plus Lofexidine for the Outpatient Treatment of Opioid Withdrawal
NCT05995535
Recruiting
A placebo-controlled trial in which male and female outpatients with an opioid use disorder who express interest in extended-release injectable naltrexone (XR-NTX) are randomized 1:1 to lofexidine/pregabalin or lofexidine/pregabalin placebo for withdrawal management and offered XR-NTX if after completing withdrawal.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/29/2025
Locations: Mountain Manor Treatment Center, Baltimore, Maryland
Conditions: Opiate Withdrawal Syndrome, Opioid Use
Register for Updates